FDA withdraws draft guidance on CBD enforcement policy

For the CBD industry, a new administration is bringing with it a regulatory setback. The Food and Drug Administration has withdrawn its draft guidance on cannabidiol enforcement policy, in-line with a directive from the Office of Management and Budget instituting a regulatory freeze as a review of new and pending rules is undertaken. 

The Council for Responsible Nutrition’s president and CEO, Steve Mister, weighed in on the “unexpected action” that the industry sees as drawing out an already protracted regulation process, noting that it presents an opportunity to underscore the importance of a legal pathway for CBD in dietary supplements. 

“CRN is reminded that we have new FDA staff to interact with and to make the case yet again why swift action from the agency is so critical to establish a legal pathway for CBD in dietary supplements,” Mister said. “We look forward to working with the new Congress and new leadership at FDA to address their concerns and promote the interests of both consumers and our members to create a well-regulated, robust and vibrant supplement marketplace for CBD.”